Skip to Main content Skip to Navigation
Journal articles

Traitement anti-angiogénique et cancer du rein : essais en cours et perspectives d'avenir [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]

Abstract : Anti-angiogenic agents have modified therapeutic strategies in the management of metastatic renal cell carcinoma. Regarding molecules that already available such as sunitinib, sorafenib, temsirolimus and bevacizumab, clinical trials are now focused on the improvement of their effectiveness, overall survival, response's criteria and toxicity. In the light of recent data, these treatments will be tested in adjuvant situation to radical nephrectomy, but also as an alternative option to radical surgery. The place of radical nephrectomy in metastatic renal cell carcinoma has been recently strongly discussed. I n the future, the systematic radical surgery will not be a rule any more. From now on, renal cell carcinoma patients have to be included in numerous ongoing therapeutic trials to manage anti-angiogenic agents in the best manner.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00325619
Contributor : Hervé de Villemeur <>
Submitted on : Monday, September 29, 2008 - 5:34:33 PM
Last modification on : Wednesday, August 19, 2020 - 11:16:34 AM

Identifiers

Collections

Citation

Stéphane Oudard, Jean-Nicolas Cornu, Morgan Rouprêt, Jean-Jacques Patard. Traitement anti-angiogénique et cancer du rein : essais en cours et perspectives d'avenir [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives]. Progrès en Urologie, Elsevier Masson, 2008, 18 Suppl 4, pp.S77-80. ⟨10.1016/S1166-7087(08)73666-2⟩. ⟨inserm-00325619⟩

Share

Metrics

Record views

198